Added to YB: 2023-11-28
Pitch date: 2023-11-28
KNTE [bullish]
Kinnate Biopharma Inc.
+18.3%
current return
Author Info
Clark Street Value is a special sits/event-driven investor. Sign up for the newsletter.
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Kinnate Biopharma Inc., a precision oncology company, focuses on the discovery, designing, and development of small molecule kinase inhibitors for treating genomically defined cancers in the United States.
Market Cap
$125.1M
Pitch Price
$2.24
Price Target
N/A
Dividend
N/A
EV/EBITDA
0.27
P/E
-1.35
EV/Sales
N/A
Sector
Biotechnology
Category
N/A
Show full summary:
Kinnate Biopharma: Foresite/OrbiMed Potential Offer, Tang Involved Too
A summary for this pitch has not been created yet.
Read full article (1 min)